Alkeus Pharmaceuticals

Executive Summary

Alkeus Pharmaceuticals is a Boston-based biopharmaceutical company focused on developing novel therapies for severe progressive retinal diseases, including Stargardt disease and geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Founded in 2010, the company's proprietary approach targets the accumulation of toxic vitamin A dimers in the retina, a key driver of retinal degeneration. Alkeus's lead candidate, ALK-001, is a deuterated form of vitamin A designed to prevent dimer formation without compromising visual function. The company has advanced ALK-001 into clinical trials for Stargardt disease, a rare genetic condition that leads to vision loss in children and young adults, and is exploring its application in GA, a leading cause of blindness in the elderly. Alkeus has generated promising early clinical data suggesting that ALK-001 can slow retinal degeneration and preserve vision. The company is poised to report pivotal results from its ongoing Phase 2 TEASE-3 trial in Stargardt disease, which could support regulatory filings if successful. In GA, Alkeus is planning a Phase 2 trial to evaluate ALK-001's potential to slow disease progression. With a strong scientific foundation, clear unmet medical need, and a de-risked mechanism, Alkeus represents a compelling opportunity in the ophthalmology space. The company's ability to deliver on upcoming milestones and secure non-dilutive funding or partnerships will be key to its success.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 TEASE-3 top-line data in Stargardt disease65% success
• H1 2027Initiation of Phase 2 trial in geographic atrophy50% success